Evidence map›Paper›PMID 34877804›Full record

ArticleCancer communications (London, England)2022

Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci.

Jian Xu, Mayrel Palestino Dominguez, Christine Alewine

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jian XuLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-4264, United States.ORCID 0000-0002-4227-2608
Mayrel Palestino DominguezLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-4264, United States.
Christine AlewineLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-4264, United States.ORCID 0000-0003-1661-0957
National Institutes of Health · US

Funding

Precision Therapy to Target Pancreatic Ductal AdenocarcinomaZIABC011652 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALEWINE, CHRISTINE · 2015 to 2025
$7.9M
Rare Exocrine Tumors of the PancreasZIABC012041 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALEWINE, CHRISTINE · 2021 to 2025
$1.3M
Intramural NIH HHS ZIA BC011652
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA DamagePancreatic NeoplasmsAdaptor Proteins, Signal TransducingCell Cycle ProteinsHumansInhibitor of Differentiation ProteinsNeoplasm ProteinsNuclear ProteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsID3 protein, humanInhibitor of Differentiation ProteinsMDC1 protein, humanNeoplasm ProteinsNuclear Proteins

Identifiers

PMID34877804
PMCPMC8923128
OpenAlexW4200288961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.